Roche Holding AG 2016 AR2
The report outlines Roche's financial and sustainability performance for the fiscal year 2016. Key achievements include the launch of four new cancer treatments, including the immunotherapy medicine Tecentriq, and being ranked as the most sustainable healthcare company in the Dow Jones Sustainability Indices for the eighth consecutive year. Roche invested CHF 9.9 billion in research and development and expanded its global biologics manufacturing network. On the environmental front, the company reduced its absolute Scope 1 and Scope 2 greenhouse gas emissions by 8.4% and increased its share of sustainable energy to 16.2%.
Company: Roche Holding AG
Sector: Manufacturing
Country: Switzerland
Year: 2016
Type: AR2
Pages: 83
Back to company
Roche Holding AG
Annual Report
The report outlines Roche's financial and sustainability performance for the fiscal year 2016. Key achievements include the launch of four new cancer treatments, including the immunotherapy medicine Tecentriq, and being ranked as the most sustainable healthcare company in the Dow Jones Sustainability Indices for the eighth consecutive year. Roche invested CHF 9.9 billion in research and development and expanded its global biologics manufacturing network. On the environmental front, the company reduced its absolute Scope 1 and Scope 2 greenhouse gas emissions by 8.4% and increased its share of sustainable energy to 16.2%.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Jan 1, 2016 - Dec 31, 2016
Fiscal Year
2016
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women in Management
Workplace Fatalities
Employees